share_log

Ladenburg Thalmann Maintains Buy on Corvus Pharma, Raises Price Target to $10

Benzinga ·  May 30, 2023 07:07

Ladenburg Thalmann analyst Aydin Huseynov maintains Corvus Pharma (NASDAQ:CRVS) with a Buy and raises the price target from $4 to $10.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment